Beam Therapeutics (BEAM) Cash from Investing Activities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash from Investing Activities data on file, last reported at $25.3 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $25.3 million, up 120.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.9 million (down 74.49% YoY), and the FY2025 annual result was -$121.4 million, down 165.64% from the prior year.
• Cash from Investing Activities retreated to $25.3 million in Q1 2026 per BEAM's latest filing, from $108.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $126.3 million in Q4 2024 and troughed at -$537.3 million in Q1 2022.
• A 5-year average of -$17.7 million and a median of $24.7 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 3186.85% in 2023, then surged 341.43% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $113.4 million in 2022, then declined by 13.52% to $98.1 million in 2023, then grew by 28.73% to $126.3 million in 2024, then fell by 14.15% to $108.4 million in 2025, then sank by 76.69% to $25.3 million in 2026.
• Business Quant data shows BEAM's Cash from Investing Activities at $25.3 million in Q1 2026, $108.4 million in Q4 2025, and $65.7 million in Q3 2025.